Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries

<div>Associations of lipid lowering strategies<sup>†</sup> in post-MI patients according to LDL-C levels. <sup>†</sup>Other possible combinations not shown were used in less than 0.5% of cases.</div>

Cardiovascular Therapeutics

fig2

Figure 2

Figure 2: Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries 

Figure 2 | Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries 